Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Calithera Biosciences Inc CALA

Healthcare Biotechnology
Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.

Recent & Breaking News (GREY:CALA)

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Benzinga.com  February 10, 2019

Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma

GlobeNewswire February 4, 2019

Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire January 28, 2019

Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline

GlobeNewswire January 7, 2019

Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference

GlobeNewswire November 30, 2018

New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire November 9, 2018

Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights

GlobeNewswire November 7, 2018

Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

GlobeNewswire October 31, 2018

Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day

GlobeNewswire October 5, 2018

Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE® (palbociclib) and talazoparib in Combination with CB-839

GlobeNewswire October 5, 2018

Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018

GlobeNewswire September 26, 2018

Calithera Biosciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Rare Disease & Oncology Roundtable

GlobeNewswire September 24, 2018

Calithera Biosciences to Participate in the Citi 13th Annual Biotech Conference and the Wells Fargo Healthcare Conference

GlobeNewswire August 29, 2018

Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 14, 2018

Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights

GlobeNewswire August 7, 2018

Calithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

GlobeNewswire August 1, 2018

Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June

GlobeNewswire June 6, 2018

Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)

GlobeNewswire June 4, 2018

Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National Instruments with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire May 16, 2018

Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights

GlobeNewswire May 10, 2018